Implications of COVID-19 infection on patients with uveitis under biologic treatment

Background/aimsTo investigate the incidence, severity of COVID-19 infection and the outcomes in patients with uveitis treated with biologic agents during COVID-19 pandemic.MethodsIn this prospective study, we included all patients with uveitis treated with biologic agents and tested for COVID-19 inf...

Full description

Saved in:
Bibliographic Details
Published inBritish journal of ophthalmology Vol. 106; no. 11; pp. 1538 - 1541
Main Authors AlBloushi, Abdulrahman F, Alfawaz, Abdullah M, Abu El Asrar, Ahmed M
Format Journal Article
LanguageEnglish
Published BMA House, Tavistock Square, London, WC1H 9JR BMJ Publishing Group Ltd 01.11.2022
BMJ Publishing Group LTD
BMJ Publishing Group
Subjects
Age
Biological products
Body mass index
Clinical Science
Coronaviruses
COVID-19
Disease transmission
immunology
infection
Infections
Inflammation
Medical supplies
Monoclonal antibodies
Ophthalmology
Pandemics
Patients
Sarcoidosis
COVID-19
immunology
infection
Online AccessGet full text

Cover

More Information
Summary:Background/aimsTo investigate the incidence, severity of COVID-19 infection and the outcomes in patients with uveitis treated with biologic agents during COVID-19 pandemic.MethodsIn this prospective study, we included all patients with uveitis treated with biologic agents and tested for COVID-19 infection between May 2020 and October 2020.ResultsA total of 59 patients were identified. Behçet’s disease was the most common diagnosis (64.4%). Infliximab was the most frequent biologic agent used (61%). Nine (15.3%) patients were tested positive for COVID-19. None of the patients with positive COVID-19 test developed any COVID-19-related symptoms during follow-up. Of the nine patients with positive COVID-19 test, only two patients had uveitis flare-up after the biologic suspension.ConclusionUveitis patients under biologic therapy can be silent carriers for COVID-19.
ISSN:0007-1161
1468-2079
DOI:10.1136/bjophthalmol-2020-318577